Linked Life Data

20926018

Source:http://linkedlifedata.com/resource/pubmed/id/20926018

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-10-7
pubmed:abstractText
The secreted glycoprotein YKL-40 is a member of the chitinase family and elevated serum YKL-40 levels have been reported to be associated with reduced survival in several malignancies, including endometrial cancer. This study investigated immunoreactivity to YKL-40 protein and its prognostic implications in endometrial cancer. Levels of YKL-40 protein in normal endometrium (n = 42), endometrial hyperplasia (n = 40) and endometrial adeno carcinoma (n = 68) were examined using immunohistochemistry. YKL-40 immunoreactivity was significantly higher in endometrial adenocarcinoma compared with hyperplastic and normal endo metrium. In addition, high immuno reactivity of YKL-40 protein was associated with advanced stage, high histological grade, lymph node metastasis and lympho vascular invasion. Moreover, positive immunoreactivity for YKL-40 was a significant predictor of poor prognosis, as measured by estimated progression-free survival and estimated overall survival, compared with negative immunoreactivity. In conclusion, high YKL-40 immuno reactivity in endometrial cancer may be associated with poor prognosis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0300-0605
pubmed:author
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1448-57
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed:articleTitle
YKL-40 protein levels and clinical outcome of human endometrial cancer.
pubmed:affiliation
Department of Obstetrics and Gynaecology, The First Affiliated Hospital, Harbin Medical University, Harbin, China.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't